# US 2012/0251528 A1 · Non-Human Mammal Model Of Human Hematopoietic Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251528 A1
- Document ID: US20120251528A1
- Status: Published application
- Kind: A1
- Application number: 13/381,307
- Filed: 2010-06-28
- Published: 2012-10-04
- Earliest claimed: 2009-06-29
- Inventors: Ilya B. Leskov; Adam C. Drake; Maroun Khoury; Jianzhu Chen; Christian Pallasch; Michael Hemann
- Web page: https://patentgrep.com/patent/US20120251528A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A01K 67/027: New or modified breeds of vertebrates
- A01K 67/0271: Chimeric vertebrates, e.g. comprising exogenous cells
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2893: {against CD52}
- A01K 2207/12: Animals modified by administration of exogenous cells
- A01K 2227/105: Murine
- A01K 2267/0331: Animal model for proliferative diseases
- A01K 2267/0381: Animal model for diseases of the hematopoietic system
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.

## Claims

### Claim 1

A method of producing a non-human mammal that is a model for a human hematopoietic cancer comprising
a) introducing human hematopoietic stem cells (HSCs) genetically engineered to express one or more human oncogenes that are associated with human hematopoietic cancer into an immunodeficient non-human mammal; and
b) maintaining the mammal under conditions in which the non-human mammal's blood cell lineage is reconstituted by the human HSCs and the oncogenes are expressed in the mammal, thereby producing a non-human mammal that is a model for a human hematopoietic cancer.

### Claim 2 (depends on 1)

The method of claim 1 wherein the immunodeficient non-human mammal is a mouse.

### Claim at position 3

3-5. (canceled)

### Claim 6 (depends on 2)

The method of claim 2 wherein the mouse is a model of a human lymphoma or a human leukemia.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The method of claim 1 wherein the one or more oncogenes are myc, bcl-2, ABL, AKT, RAS, BRAC1, BRAC2, CBL, CDK4, CDK6, PML, mutant IDH1, mutant IDH2 or a combination thereof.

### Claim 9 (depends on 8)

The method of claim 8 wherein the HSCs are transfected with a virus expressing the myc oncogene, the bcl-2 oncogene or the combination thereof.

### Claim at position 8

10-16. (canceled)

### Claim 17 (depends on 1)

The method of claim 1 wherein the HSCs are expanded in vitro by culturing the HSCs in serum-free media supplemented with growth factors.

### Claim 18

(canceled)

### Claim 19 (depends on 17)

The method of claim 17 wherein the growth factors are stem cell factor, thrombopoietin, fibroblast growth factor 1, insulin growth factor binding protein 2 (IGFBP2), angiopoietin-like protein 5 (Angptl5), or a combination thereof.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The method of claim 1 wherein the HSCs are obtained from a cancer patient.

### Claim 22 (depends on 21)

The method of claim 21 wherein the cancer patient has a lymphoid cancer or a leukemia.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The method of claim 1 further comprising assessing the reconstitution of the non-human mammal's blood cell lineage by the human HSCs in the non-human mammal.

### Claim 25

(canceled)

### Claim 26 (depends on 1)

The method of claim 1 further comprising producing one or more non-human mammals that are models for a human hematopoietic cancer comprising
c) introducing the human cells that express the one or more human oncogenes obtained from the non-human mammal of step b) into the one or more immunodeficient non-human mammals; and
d) maintaining the one or more non-human mammals of c) under conditions in which the one or more non-human mammal's blood cell lineage is reconstituted by the human HSCs and the oncogenes are expressed in the one or more non-human mammals, thereby producing one or more non-human mammals that are models for a human hematopoietic cancer.

### Claim at position 19

27-28. (canceled)

### Claim 29 (depends on 26)

The method of claim 26 wherein the immunodeficient non-human mammal is a mouse.

### Claim at position 21

30-31. (canceled)

### Claim 32 (depends on 29)

The method of claim 29 wherein the mouse is a model of a human lymphoma or a human leukemia.

### Claim 33

(canceled)

### Claim 34 (depends on 1)

The method of claim 1 further comprising introducing HSCs genetically engineered to comprise nucleic acid that inhibits one or more tumor suppressor genes in the HSCs, in the progeny of the HSCs or in a combination thereof.

### Claim 35

A method of producing a non-human mammal that is a model for a human hematopoietic cancer comprising
a) introducing human hematopoietic stem cells (HSCs) genetically engineered to comprise nucleic acid that inhibits one or more tumor suppressor genes in the HSCs, in the progeny of the HSCs or in a combination thereof into an immunodeficient non-human mammal; and
b) maintaining the mammal under conditions in which the non-human mammal's blood cell lineage is reconstituted by the human HSCs and expression of the one or more tumor suppressors genes are inhibited in the mammal, thereby producing a non-human mammal that is a model for a human hematopoietic cancer.

### Claim 36 (depends on 1)

A non-human mammal that is a model for a human hematopoietic cancer produced by the method of claim 1.

### Claim at position 27

37-41. (canceled)

### Claim 42

A method of producing a non-human mammal that is a model for a human hematopoietic cancer patient comprising introducing hematopoietic stem cells (HSCs) of the hematopoietic cancer patient into an immunodeficient non-human mammal and maintaining the non-human mammal under conditions in which the non-human mammal's blood cell lineages is reconstitute by the HSCs and the one or more oncogenes of the cancer patient are expressed in the mammal, thereby producing a non-human mammal that is a model for the hematopoietic cancer patient.

### Claim at position 29

43-47. (canceled)

### Claim 48 (depends on 42)

The method of claim 42 further comprising administering an agent or a treatment to the non-human mammal that is a model for the hematopoietic cancer patient and determining whether the agent or the treatment can be used to treat the cancer patient.

### Claim 49

(canceled)

### Claim 50 (depends on 36)

A method of identifying one or more agents or treatment regimens that can be used to treat a human hematopoietic cancer comprising
a) administering the one or more agents to a non-human mammal of claim 36; and
b) determining whether the cancer in the non-human mammal is alleviated, wherein if the cancer in the non-human mammal is alleviated in the non-human mammal, then the one or more agents or treatment protocols can be used to treat the human hematopoietic cancer.

### Claim at position 33

51-52. (canceled)

### Claim 53 (depends on 50)

The method of claim 50 wherein two or more agents are administered to the non-human mammal.

### Claim 54 (depends on 53)

The method of claim 53 wherein administration of the two agents results in a synergistic effect for the treatment of human B cell cancer.

### Claim 55

A method of treating leukemia in an individual in need thereof comprising simultaneously administering an effective amount of an anti-CD52 antibody and one or more chemotherapeutic agents to the individual.

### Claim 56 (depends on 55)

The method of claim 55 wherein the anti-CD52 antibody is alemtuzumab and the one or more chemotherapeutic agents is cyclophosphamide.

### Claim 57 (depends on 56)

The method of claim 56 wherein the cancer cell load in bone marrow of the individual is reduced 10,000-fold after administration of the alemtuzumab and the cyclophosphamide.
